CVS Health Corporation $CVS Stock Position Lifted by Cloverfields Capital Group LP

Cloverfields Capital Group LP grew its position in shares of CVS Health Corporation (NYSE:CVS) by 10.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 62,573 shares of the pharmacy operator’s stock after buying an additional 5,723 shares during the period. CVS Health comprises 1.5% of Cloverfields Capital Group LP’s portfolio, making the stock its 28th largest position. Cloverfields Capital Group LP’s holdings in CVS Health were worth $4,966,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the company. Storgate LLC bought a new position in CVS Health during the 4th quarter worth approximately $480,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in CVS Health by 4.9% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 8,312,341 shares of the pharmacy operator’s stock worth $659,667,000 after buying an additional 387,467 shares during the last quarter. Korea Investment CORP lifted its holdings in CVS Health by 17.9% during the 4th quarter. Korea Investment CORP now owns 956,189 shares of the pharmacy operator’s stock worth $75,883,000 after buying an additional 144,838 shares during the last quarter. Lord Abbett & CO. LLC raised its position in shares of CVS Health by 12.9% during the 4th quarter. Lord Abbett & CO. LLC now owns 3,012 shares of the pharmacy operator’s stock worth $239,000 after purchasing an additional 344 shares during the period. Finally, Rhenman & Partners Asset Management AB raised its position in shares of CVS Health by 21.0% during the 4th quarter. Rhenman & Partners Asset Management AB now owns 335,500 shares of the pharmacy operator’s stock worth $26,625,000 after purchasing an additional 58,138 shares during the period. Institutional investors own 80.66% of the company’s stock.

Insider Activity at CVS Health

In related news, EVP Tilak Mandadi sold 69,551 shares of the firm’s stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $89.58, for a total value of $6,230,378.58. Following the sale, the executive vice president directly owned 10,133 shares in the company, valued at $907,714.14. This trade represents a 87.28% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Larry Robbins sold 370,462 shares of CVS Health stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $93.45, for a total value of $34,619,673.90. Following the transaction, the director owned 4,824,799 shares in the company, valued at approximately $450,877,466.55. This trade represents a 7.13% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 3,441,551 shares of company stock worth $323,703,977. 0.85% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on CVS shares. Sanford C. Bernstein increased their price target on CVS Health from $94.00 to $106.00 and gave the stock an “outperform” rating in a research report on Tuesday, May 12th. TD Cowen increased their price target on CVS Health from $105.00 to $110.00 and gave the stock a “buy” rating in a research report on Monday, May 11th. Cantor Fitzgerald reiterated an “overweight” rating on shares of CVS Health in a research report on Thursday. Wall Street Zen cut CVS Health from a “buy” rating to a “hold” rating in a research report on Saturday. Finally, JPMorgan Chase & Co. increased their price target on CVS Health from $101.00 to $111.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 12th. Twenty-two research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $100.68.

CVS Health News Roundup

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS is expanding access to GLP-1 weight-loss drugs, including bringing back Zepbound and loosening restrictions on newer oral therapies, which could improve customer engagement and prescription volume while supporting its broader healthcare platform. Is CVS (CVS) Using GLP-1 Access and AI Tools to Redefine Its Healthcare Moat?
• Positive Sentiment: The company is also pushing AI deeper into pharmacy, insurance, and care delivery operations, aiming to cut administrative burden, improve efficiency, and potentially widen margins over time. Healthy Returns: CVS Health executives on reducing health care’s biggest pain points
• Positive Sentiment: CVS Health has launched Aetna Mental Health on Demand, which gives members faster access to care and shows the company is trying to strengthen service offerings across its insurance business. 5 Low Price-to-Book Stocks That Are Worth Buying in June
• Positive Sentiment: Recent coverage notes CVS at a 52-week high and highlights strong post-earnings momentum, while screening screens and “trending stock” mentions suggest investor interest remains elevated. CVS Health Corporation (CVS) Hit a 52 Week High, Can the Run Continue?
• Neutral Sentiment: CVS is also working with Fluency to move autonomous AI agents from pilot projects into production, but the financial impact is still early and not yet quantified. CVS is Using Fluency to Close Enterprise AI Deployment Gap
• Neutral Sentiment: News that Mass General Brigham and CVS are moving closer to a primary care partnership and that the stock is being heavily discussed by retail investors adds attention, but these items are not immediate earnings drivers. Mass General Brigham and CVS primary care partnership moves closer to reality
• Negative Sentiment: Musab Balbale’s departure adds some leadership turnover, though the market may view it as a limited issue unless more executive changes follow. Musab Balbale Departs CVS Health

CVS Health Stock Up 1.4%

CVS opened at $101.87 on Friday. CVS Health Corporation has a 12 month low of $58.50 and a 12 month high of $102.77. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.87 and a quick ratio of 0.66. The stock has a market cap of $129.98 billion, a P/E ratio of 44.88, a P/E/G ratio of 0.98 and a beta of 0.62. The stock’s 50 day moving average price is $86.91 and its 200 day moving average price is $80.78.

CVS Health (NYSE:CVS) last posted its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, beating the consensus estimate of $2.21 by $0.36. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The firm had revenue of $100.43 billion for the quarter, compared to analysts’ expectations of $94.99 billion. During the same period last year, the firm earned $2.25 EPS. The firm’s revenue was up 6.2% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. As a group, research analysts predict that CVS Health Corporation will post 7.44 earnings per share for the current year.

CVS Health Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, May 4th. Investors of record on Thursday, April 23rd were given a $0.665 dividend. This represents a $2.66 annualized dividend and a yield of 2.6%. The ex-dividend date was Thursday, April 23rd. CVS Health’s dividend payout ratio (DPR) is currently 117.18%.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over?the?counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in?store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk?in medical clinics and HealthHUB locations that offer expanded clinical services.